Fundraising Fox
Synendos
Basel, CH · Founded 2019 · 17 employees on LinkedIn · 11 known investors
Find your way into Synendos
Sign up to see every warm intro you have to Synendos
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Synendos team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders. The company's lead candidate, SYT-510, is in clinical development with the goal of restoring brain function in major psychiatric and neurological conditions.
Founders & leadership
Synendos was founded in 2019 by Prof. Jürg Gertsch, Dr. Andrea Chicca, and Dr. Simon Russell.
Investors · 11
How we know: Kurma Partners's portfolio page · the company's own site · funding news · prnewswire.com · the VCSheet dataset · Not right? Tell us
How we know: Ysios Capital's portfolio page · the company's own site · funding news · the VCSheet dataset · Not right? Tell us
How we know: High Tech Gruenderfonds's portfolio page · Not right? Tell us
How we know: Sunstone Capital's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
Also in the syndicate · 7
Funding
SEC filings, press & company announcements- Undisclosed amountSeries ANov 2020
Kurma Partners (lead), Sunstone Life Science Ventures (lead), BERNINA BioInvest, Essential Investments, High-Tech Gründerfonds, Lichtsteiner Foundation, Schroder Adveq, Zürcher Kantonalbank
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Synendos do?
- Synendos is a biotech company developing selective endocannabinoid reuptake inhibitors targeting the endocannabinoid system to treat neuropsychiatric disorders. The company's lead candidate, SYT-510, is in clinical development with the goal of restoring brain function in major psychiatric and neurological conditions.
- Who founded Synendos?
- Synendos was founded by Prof. Jürg Gertsch, Dr. Andrea Chicca, Dr. Simon Russell in 2019.
- Who are Synendos's investors?
- Synendos's investors include Kurma Partners, Ysios Capital, High Tech Gruenderfonds, Sunstone Capital.
- Where is Synendos headquartered?
- Synendos is headquartered in Basel, CH.